YU47650B - Stabilna mikrosferna kompozicija i postupak za njeno dobijanje - Google Patents

Stabilna mikrosferna kompozicija i postupak za njeno dobijanje

Info

Publication number
YU47650B
YU47650B YU57091A YU57091A YU47650B YU 47650 B YU47650 B YU 47650B YU 57091 A YU57091 A YU 57091A YU 57091 A YU57091 A YU 57091A YU 47650 B YU47650 B YU 47650B
Authority
YU
Yugoslavia
Prior art keywords
weight
biologically active
composition
active protein
oil
Prior art date
Application number
YU57091A
Other languages
English (en)
Other versions
YU57091A (sh
Inventor
W. Steber
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Publication of YU57091A publication Critical patent/YU57091A/sh
Publication of YU47650B publication Critical patent/YU47650B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Abstract

naznačen time, što obuhvata od oko 30 mas.% do 95 mas.% masti ili voska koji imaju temperaturu topljenja iznad 40В°C, ili njihove smese; oko 2 mas.% do 70 mas.% biološki aktivnog proteina, peptida ili polipeptida; i oko 1 mas.% do 30 mas.% ulja, semi-tečne masti, koji imaju temperaturu topljenja na ili blizu sobne temperature, ili njihove smese. Stabilna mikrosferna kompozicija prema zahtevu 1, naznačena time, što sadrži oko 5 mas.% do 20 mas.% neutralnog triglicerol ulja a biološki aktivan protein je hormon rasta govečeta, svinje ili ptičiji hormon rast. Postupak za dobijanje stabilne mikrosferne kompozicije, koji obuhvata faze mešanja rastopa masti ili voska ili njihove smese, i biološki aktivnog proteina, peptida ili polipeptida radi obrazovanja mešavine i očvršćavanje te mešavine rasprskavan-jem radi obrazovanja mikrosferne kompozicije, naznačen ti me, što seu mešavinu koja se sastoji od oko 30 do 95 mas% masti ili voska ili njihove smole, od oko 2 do 70 mas.% biološki aktivnog proteina, kao što je peptid ili polipeptid, najbolje hormona rasta govečeta, svinje ili ptice i oko 5 do 20 mas.% neutralnog triglicerol ulja, pre njenog očvršćavanja rasprskavanjem, umešava oko 1 mas.% do 30 mas.% ulja, semi-tečne masti, sa temperaturom topljenja na ili blizu sobnoj temperaturi, ili njihove smese, i što se dobijena mikros-ferna kompozicija suspenduje u tečnom nosaču.- Prijava sadrži još 2 zavisna zahteva.
YU57091A 1990-03-30 1991-03-29 Stabilna mikrosferna kompozicija i postupak za njeno dobijanje YU47650B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/502,382 US5213810A (en) 1990-03-30 1990-03-30 Stable compositions for parenteral administration and method of making same

Publications (2)

Publication Number Publication Date
YU57091A YU57091A (sh) 1994-01-20
YU47650B true YU47650B (sh) 1995-12-04

Family

ID=23997559

Family Applications (1)

Application Number Title Priority Date Filing Date
YU57091A YU47650B (sh) 1990-03-30 1991-03-29 Stabilna mikrosferna kompozicija i postupak za njeno dobijanje

Country Status (29)

Country Link
US (1) US5213810A (sh)
EP (1) EP0448930B1 (sh)
JP (1) JP2966564B2 (sh)
KR (1) KR0159778B1 (sh)
CN (1) CN1063941C (sh)
AR (1) AR248085A1 (sh)
AT (1) ATE106240T1 (sh)
AU (1) AU641994B2 (sh)
BG (1) BG60850B1 (sh)
CA (1) CA2039491C (sh)
CZ (1) CZ283053B6 (sh)
DE (1) DE69102176T2 (sh)
DK (1) DK0448930T3 (sh)
ES (1) ES2054380T3 (sh)
FI (1) FI101676B (sh)
HK (1) HK1000004A1 (sh)
HU (1) HU219584B (sh)
IE (1) IE65970B1 (sh)
IL (1) IL97145A (sh)
MX (1) MX172602B (sh)
NO (1) NO300717B1 (sh)
NZ (1) NZ237509A (sh)
PL (1) PL167692B1 (sh)
PT (1) PT97160B (sh)
RO (1) RO106191B1 (sh)
RU (1) RU2011377C1 (sh)
SK (1) SK279461B6 (sh)
YU (1) YU47650B (sh)
ZA (1) ZA912398B (sh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134873T1 (de) * 1991-07-23 1996-03-15 American Cyanamid Co Stabile zusammensetzungen für parenterale verabrechung und ihre verwendung
WO1994017106A1 (en) * 1993-01-19 1994-08-04 Pharmacia P-L Biochemicals, Inc. Storage and delivery of purified protein reagents with carrier wax
US5599660A (en) * 1993-01-19 1997-02-04 Pharmacia Biotech Inc. Method and preparation for sequential delivery of wax-embedded, inactivated biological and chemical reagents
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5683720A (en) * 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
AU2002300572B2 (en) * 1997-09-19 2004-11-25 Shire Laboratories, Inc. Solid Solution Beadlet
AU9496798A (en) 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
CA2369594A1 (en) * 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
CA2376202C (en) * 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
US6544646B2 (en) 2000-04-27 2003-04-08 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
WO2002000028A1 (en) * 2000-06-26 2002-01-03 Martek Biosciences Boulder Corporation Improved methods of incorporating polyunsaturated fatty acids in milk
WO2002026372A2 (en) 2000-09-27 2002-04-04 Verion Inc. Instant water dissolvable encapsulate and process
ATE392887T1 (de) * 2000-10-10 2008-05-15 Wyeth Corp Stabilisierte arzneizusammensetzungen zur parenteralen vearbreichung
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
WO2005053651A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053655A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547773A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8221809B2 (en) * 2006-06-22 2012-07-17 Martek Biosciences Corporation Encapsulated labile compound compositions and methods of making the same
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
JP5494957B2 (ja) 2009-06-11 2014-05-21 株式会社リコー 静電荷像現像用トナー、現像剤、画像形成方法及び画像形成装置
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9364549B2 (en) * 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
EP3003266A2 (en) * 2013-05-29 2016-04-13 Therakine Biodelivery GmbH Hydrophilic microparticles, drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
EP3458084B1 (en) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
EP3927715A4 (en) * 2019-02-21 2023-03-01 Chromadex, Inc. USE OF NICOTINAMIDE RIBOSIDE, NICOTINOIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS AND NICOTINYL RIBOSIDE COMPOUNDS IN FORMULATIONS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
DE3024416C2 (de) * 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4666839A (en) * 1982-12-01 1987-05-19 Amgen Methods and materials for obtaining microbial expression of polypeptides including bovine prolactin
US4452775A (en) * 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
DE3527356A1 (de) * 1985-07-31 1987-02-05 Degussa Verfahren zur verbesserung der fruchtbarkeit von haustieren
SE462894B (sv) * 1985-10-28 1990-09-17 Biogram Ab Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles

Also Published As

Publication number Publication date
AU641994B2 (en) 1993-10-07
KR0159778B1 (ko) 1998-12-01
PL167692B1 (en) 1995-10-31
PT97160B (pt) 1998-07-31
DE69102176T2 (de) 1995-01-05
AU7397291A (en) 1991-10-03
HK1000004A1 (en) 1997-10-03
MX172602B (es) 1993-01-03
EP0448930A1 (en) 1991-10-02
FI101676B1 (fi) 1998-08-14
CN1063941C (zh) 2001-04-04
IL97145A (en) 1996-06-18
YU57091A (sh) 1994-01-20
US5213810A (en) 1993-05-25
KR910016322A (ko) 1991-11-05
HU219584B (hu) 2001-05-28
JP2966564B2 (ja) 1999-10-25
CA2039491A1 (en) 1991-10-01
BG60850B1 (bg) 1996-05-31
NO911228D0 (no) 1991-03-26
PL289657A1 (en) 1992-01-13
DK0448930T3 (da) 1994-06-20
IE65970B1 (en) 1995-11-29
DE69102176D1 (de) 1994-07-07
ES2054380T3 (es) 1994-08-01
FI911531A0 (fi) 1991-03-28
IE911041A1 (en) 1991-10-09
CN1055293A (zh) 1991-10-16
NZ237509A (en) 1993-04-28
ZA912398B (en) 1992-01-29
FI911531A (fi) 1991-10-01
JPH04221319A (ja) 1992-08-11
PT97160A (pt) 1991-11-29
ATE106240T1 (de) 1994-06-15
SK279461B6 (sk) 1998-11-04
FI101676B (fi) 1998-08-14
EP0448930B1 (en) 1994-06-01
RO106191B1 (ro) 1993-03-31
CZ283053B6 (cs) 1997-12-17
HU911054D0 (en) 1991-10-28
IL97145A0 (en) 1992-05-25
RU2011377C1 (ru) 1994-04-30
NO911228L (no) 1991-10-01
NO300717B1 (no) 1997-07-14
AR248085A1 (es) 1995-06-30
CA2039491C (en) 2001-09-04
HUT59834A (en) 1992-07-28

Similar Documents

Publication Publication Date Title
YU47650B (sh) Stabilna mikrosferna kompozicija i postupak za njeno dobijanje
EP0049469B2 (de) Kollagene Wundauflage
ES2054842T3 (es) Analogo del factor viii, procedimiento de preparacion y composicion farmaceutica que lo contiene.
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
MX9206315A (es) Heterodimeros recombinantes de proteinas morfogenicas de hueso, composiciones de estos y metodos para su uso.
KR910700264A (ko) 소마토트로핀 유사물
DE3486154D1 (de) Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
ES2039219T3 (es) Composiciones para administracion parenteral y su uso.
PT97539A (pt) Estabilizacao de somatotropinas e outras proteinas por modificacao dos residuos sw cisteina
DK336986D0 (da) Fremgangsmaade til fremstilling af toerre biologisk aktive rekombinante vaeksthormoner
OA07893A (fr) Compositions rodenticides et leur application.
US3016334A (en) Skin cream containing low gel strength, low viscosity gelatin
DK138285D0 (da) Indkapslet lipidmateriale, isaer til brug i foder, og fremgangsmaade til dets fremstilling
ATE182793T1 (de) Zusammensetzung und verfahren zur verhinderung und behandlung von entzündung mit immunoglobin a
DE69122267D1 (de) Verfahren zum beimischen von zuschlagstoffen in eine versprühte betonmasse und wirkstoff zur anwendung des verfahrens
KR930000131A (ko) 생물학적으로 활성 단백질, 펩티드 또는 폴리펩티드를 함유하는 이식재 조성물 및 그의 제조방법
ES2180553T3 (es) Cemento para uso medico, procedimiento para fabricar el cemento y su utilizacion.
KR910003095A (ko) 사람의 단백질 c변이체 및 이의 제조방법
ES2120461T3 (es) Composicion plaguicida.
JPS6061509A (ja) 吸血性環形動物忌避剤
DE3874320D1 (de) Tablette zur behandlung bei progesteronmangel.
DE69218136T2 (de) Verpackungs- und Abgabesystem für flüssige und halbflüssige Zementzusatzmittel
Yabu et al. Immunohistochemical, autoradiographic and electron microscopic studies on the transformation of fibroblasts into chondrocytes in the mouse subfascia induced by bone morphogenetic protein
DE69129036D1 (de) Überdeckte zusammensetzung mit schneller freisetzung
KR890005149A (ko) 합성 펩타이드 및 이를 포함한 제약학적 조성물